← All trials
NCT04562766
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2020
- Primary completion
- Oct 31, 2023
- Completion date
- Jun 30, 2025
- First posted
- Sep 24, 2020
- Last posted
- Dec 24, 2020
- Enrollment
- 194
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Principia Biopharma, Inc.Lead sponsor
- Principia Biopharma, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.